Clinical Trial Update: Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis. [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing tigecycline to ertapenem for diabetic foot infections (including an osteomyelitis substudy) has completed and results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Infection
• Osteomyelitis

Drugs mentioned

• Invanz (ertapenem)
• TYGACIL (tigecycline)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Bacterial Infections, Diabetic Foot | Phase 3 | Status: COMPLETED | Results posted: 2009-08-21